Xilio Therapeutics Profit Margin

The latest profit margin for XLO is -8.65% as of June 2026. That compares with -192.9% in the prior-year period — up 95.5% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Xilio Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, XLO's profit margin moved from -192.9% to -8.65% — a 95.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Xilio Therapeutics's valuation or profitability profile.

Against Healthcare companies, XLO currently prints -8.65% for profit margin, while the sector average sits near 13.89%. That is roughly 162.2% below the sector mean. Large gaps often invite a closer look at Xilio Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Xilio Therapeutics converts resources into returns. At -8.65%, XLO may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -192.9% in the prior-year period — up 95.5% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting XLO's profit margin (-8.65%), review year-over-year change from -192.9%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.